Tocilizumab

Study	No of events / total Experimental	Control	Odds Ratio [95% CI]
BACC–Bay	0 / 3	0 / 1	0.43 [0.01, 33.60]
COVIDOSE2–SS–A	0 / 6	1 / 2	0.08 [0.00, 2.99]
ARCHITECTS	0 / 9	2 / 11	0.20 [0.01, 4.75]
CORIMUNO–TOCI–1	1 / 10	3 / 12	0.33 [0.03, 3.84]
CORIMUNO–TOCI–ICU	4 / 8	2 / 4	1.00 [0.09, 11.03]
ImmCOVA	2 / 21	2 / 26	1.26 [0.16, 9.81]
COV–AID	6 / 48	3 / 42	1.86 [0.43, 7.94]
HMO–020–0224	10 / 31	8 / 15	0.42 [0.12, 1.47]
TOCIBRAS	8 / 31	5 / 34	2.02 [0.58, 7.00]
COVACTA	14 / 56	12 / 41	0.81 [0.33, 1.99]
EMPACTA	24 / 200	11 / 112	1.25 [0.59, 2.66]
PreToVid	20 / 159	32 / 167	0.61 [0.33, 1.11]
REMDACTA	69 / 358	39 / 181	0.87 [0.56, 1.35]
REMAP–CAP	53 / 214	73 / 217	0.65 [0.43, 0.99]
RECOVERY	482 / 1664	600 / 1721	0.76 [0.66, 0.88]
Total (95% CrI)	**693 / 2818**	**793 / 2586**	0.78 [0.65, 0.94]
τ = 0.11 [95% CrI: 0.02, 0.25]			PI: [0.56, 1.10]

Favors Experimental / Favors Control

Odds Ratio (log scale): 0.25 0.5 1 2 4

Baricitinib

Study	No of events / total Experimental	Control	Odds Ratio [95% CI]
ACTT–2	9 / 106	15 / 118	0.64 [0.27, 1.52]
COV–BARRIER	57 / 612	82 / 592	0.64 [0.45, 0.91]
COV–BARRIER 2	16 / 43	26 / 44	0.41 [0.17, 0.97]
Total [95% CrI]	**82 / 761**	**123 / 754**	0.61 [0.42, 0.89]
τ = 0.13 [95% CrI: 0.02, 0.34]			PI: [0.35, 0.99]

Sarilumab

Study	No of events / total Experimental	Control	Odds Ratio [95% CI]
CORIMUNO–SARI–1	0 / 3	2 / 4	0.14 [0.00, 4.47]
REGENERON–P2	27 / 62	5 / 14	1.39 [0.42, 4.62]
REGENERON–P3	84 / 345	24 / 99	1.01 [0.60, 1.69]
REMAP–CAP	8 / 44	13 / 52	0.67 [0.25, 1.79]
SARCOVID	1 / 17	0 / 8	1.55 [0.06, 42.15]
SARICOR	2 / 66	3 / 34	0.32 [0.05, 2.03]
SARTRE	2 / 70	1 / 70	2.03 [0.18, 22.91]
Total [95% CrI]	**124 / 607**	**48 / 281**	0.92 [0.60, 1.41]
τ = 0.13 [95% CrI: 0.02, 0.35]			PI: [0.52, 1.62]

Favors Experimental / Favors Control

Odds Ratio (log scale): 0.25 0.5 1 2 4